Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest celiac disease Stories

2013-11-05 12:28:04

BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO). Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008. Under her leadership, Alba Therapeutics established a collaborative funding...

2013-11-04 08:25:55

- Study expected to begin by end of 2013 - JERUSALEM, Nov. 4, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease. The study is expected to begin by the end of this year. (Logo:...

2013-09-24 08:29:52

- Study expected to begin in Q4 2013 - JERUSALEM, Sept. 24, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study. (Logo:...

2013-09-09 08:27:20

CAMBRIDGE, Mass., Sept. 9, 2013 /PRNewswire/ -- ImmusanT announced today that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief Medical Officer. Dr. Massari will oversee the clinical development program for the therapeutic vaccine Nexvax2® for celiac disease and its companion diagnostic, as well as future development programs for other autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20130909/LA75726LOGO)...

2013-08-29 23:25:28

Just a few years ago, most Americans had never heard of celiac disease. But today, an estimated 1 in 133 Americans has celiac disease and seniors are more than twice as likely as the general population to suffer from it. Des Moines, IA (PRWEB) August 29, 2013 Just a few years ago, most Americans had never heard of “celiac disease” or the term “gluten-intolerant.” But today, an estimated 1 in 133 Americans, or about 1-percent of the population, has celiac disease. So what is it?...

2013-08-28 08:25:52

JERUSALEM, Aug. 28, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th International Celiac Disease Symposium, which will take place September 22-25, 2013 in Chicago. Yotam Nisemblat, Senior Drug Development Manager at BioLineRx, will present BL-7010 for the treatment of...

2013-08-27 20:22:42

CAMBRIDGE, Mass., Aug. 27, 2013 /PRNewswire/ -- Researchers have developed a new approach to detecting unrecognized cases of celiac disease in the community, revealing this immune disorder is far more common than previously recognized. In a study of more than 2500 adults, the researchers combined traditional antibody testing (measuring the immune response to gluten) with an assessment of specific genetic risk markers. They found that more than half of the subjects had genetic risk...

2013-08-06 12:16:32

Patients with celiac disease who had persistent intestine damage (identified with repeat biopsy) had a higher risk of lymphoma than patients whose intestines healed, according to findings published in the August 6, 2013, issue of Annals of Internal Medicine. Celiac disease is a common autoimmune disease, affecting approximately one percent of individuals in Western nations. It is characterized by damage to the lining of the small intestine that over time reduces the body's ability to...

2013-08-06 08:33:32

CAMBRIDGE, Mass., Aug. 6, 2013 /PRNewswire/ -- ImmusanT today announced that it has initiated a clinical research study to explore the immunologic relationship between celiac disease and Type 1 diabetes (T1D) and to further understand the underlying cause of T1D. The research will focus on characterizing immune responses in patients affected by both T1D and celiac disease. The study will be performed by the Joslin Diabetes Center. It is estimated that celiac disease affects about one...

FDA Sets New Rules On Gluten-Free Food Labeling
2013-08-02 12:58:48

Lawrence LeBlond for redOrbit.com - Your Universe Online At least three million Americans who suffer from celiac disease can now feel confident knowing tha,t when they buy a product labeled "gluten-free," they are actually getting what they expect. This comes thanks to a new FDA ruling that defines exactly what "gluten-free" means. Under the new rule, when consumers see a label that is marked "gluten-free," "without gluten," "free of gluten" or "no gluten," they can be assured that...